CD40 and esophageal cancer: In conclusion, the current study provides compelling evidence for the efficacy of a CD40 agonistic antibody in combination with neoadjuvant chemoradiation in esophageal cancer, highlighting its potential to improve clinical outcomes via enhanced immune responses.